Biofrontera (BFRI) Cash from Financing Activities (2020 - 2025)

Biofrontera's Cash from Financing Activities history runs 6 years deep, the most recent figure standing at $2.4 million for Q4 2025.

• On a quarterly basis, Cash from Financing Activities fell 41.98% year-over-year to $2.4 million in Q4 2025; TTM through Dec 2025 was $6.1 million, a 58.87% decrease from a year earlier, with the FY2025 full-year figure at $10.8 million, down 26.86% from the prior year.
• Cash from Financing Activities eased to $2.4 million in Q4 2025 per BFRI's latest filing, from $4.0 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $43.8 million in Q4 2021 and bottomed at -$298000.0 in Q3 2024.
• The 5-year median for Cash from Financing Activities is $4.3 million (2022), against an average of $7.3 million.
• Across the five-year window, Cash from Financing Activities soared 3926.45% in 2022 and plunged 150.42% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at $43.8 million in 2021, then plunged by 89.44% to $4.6 million in 2022, then surged by 45.01% to $6.7 million in 2023, then slumped by 39.68% to $4.0 million in 2024, then sank by 41.98% to $2.4 million in 2025.
• Per Business Quant, the three latest BFRI Cash from Financing Activities figures stand at $2.4 million (Q4 2025), $4.0 million (Q4 2024), and -$298000.0 (Q3 2024).